Elequin Capital’s Haemonetics HAE Stock Holding History

Elequin Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$150	Sell	2 -33	-94%	-$2.12K	﹤0.01%	648
2026 Q1	$1.97K	Sell	35 -74	-68%	-$4.82K	﹤0.01%	487
2025 Q4	$8.74K	Buy	+109	New	+$7.32K	﹤0.01%	254
2025 Q1	–	Sell	-79	Closed	-$6.17K	–	456
2024 Q4	$6.17K	Buy	79 +1	+1%	+$80	﹤0.01%	384
2024 Q3	$6.27K	Buy	+78	New	+$6.3K	﹤0.01%	278
2024 Q2	–	Sell	-7	Closed	-$597	–	256
2024 Q1	$597	Buy	+7	New	+$549	﹤0.01%	207
2023 Q3	–	Sell	-24	Closed	-$2.04K	–	491
2023 Q2	$2.04K	Buy	+24	New	+$2.03K	﹤0.01%	443
2022 Q3	–	Sell	-53	Closed	-$3K	–	607
2022 Q2	$3K	Buy	53 +4	+8%	+$237	﹤0.01%	316
2022 Q1	$3K	Buy	+49	New	+$2.67K	﹤0.01%	240

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Elequin Capital's HAE Position: Q2 2026 in Review

Elequin Capital reduced its Haemonetics (HAE) stake by 94% in Q2 2026, selling an estimated $2.12K and leaving 2 shares worth $150. The position accounts for ﹤0.01% of the portfolio, ranked #648.

Elequin Capital first reported a position in HAE in Q1 2022 and has held it in 9 quarters since. The position peaked at $8.74K in Q4 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Elequin Capital held 2 shares of Haemonetics worth $150 as of Q2 2026.
Elequin Capital sold 33 Haemonetics shares in Q2 2026, an estimated $2.12K.
Haemonetics made up ﹤0.01% of Elequin Capital's portfolio in Q2 2026, its #648 holding.
Elequin Capital first reported a position in Haemonetics in Q1 2022 and has held it in 9 quarters since.
Elequin Capital's Haemonetics position peaked at $8.74K in Q4 2025.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.